This article reviews current recommendations for breast-cancer screening and the supporting evidence, including the controversy regarding mammographic screening of women in their 40s.
Continue reading this article
Select an option below:
Create your account to get 2 free subscriber-only articles each month.
Dr. Warner reports receiving grant support from Amersham Health, consulting fees from Bayer Schering Pharma, and lecture fees from AstraZeneca.
Disclosure forms provided by the author are available with the full text of this article at NEJM.org.
No other potential conflict of interest relevant to this article was reported.
An audio version of this article is available at NEJM.org.
Author Affiliations
From the Division of Medical Oncology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto.
Address reprint requests to Dr. Warner at the Division of Medical Oncology, Sunnybrook Health Sciences Centre, 2075 Bayview Ave., Toronto, ON M4N 3M5, Canada, or at [email protected].